As one of the few evidence-based treatments shown to decrease mortality, buprenorphine use has grown in the United States and abroad. Buprenorphine is a first line option for opioid use disorder shown ...
Orexo AB (publ) announced today that the U.S. Food and Drug Administration (FDA) has approved ZUBSOLV® (buprenorphine/naloxone CIII sublingual tablet) for induction of buprenorphine maintenance ...
MedPage Today on MSN
Two extended-release buprenorphine doses effective in high-risk opioid use disorder
Extended-release buprenorphine is approved as a once-monthly subcutaneous injection for the treatment of moderate-to-severe OUD. A previous study cited by the study authors had suggested that a higher ...
The ISTART (Induction, STabilization, Adherence and Retention) Trial (Study OX219-006) was a randomized, non-inferiority, multicenter study to assess early treatment efficacy of Zubsolv versus generic ...
Please provide your email address to receive an email when new articles are posted on . Patients with untreated opioid use disorder responded well to a high-dose induction of buprenorphine in the ED, ...
ORLANDO, Florida ― Initiating unobserved buprenorphine induction to treat opioid dependence may help lower barriers to care in this population, new research suggests. Results from an observational ...
Heavy fentanyl users may derive greater benefit from a higher dose of extended-release buprenorphine maintenance therapy, a randomized controlled trial suggests.
Orexo AB (publ) announced today that the U.S. Food and Drug Administration (FDA) has approved ZUBSOLV® (buprenorphine/naloxone CIII sublingual tablet) for induction of buprenorphine maintenance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback